Scancell has reported excellent Phase 2 data from its SCOPE study, with its lead cancer vaccine SCIB1/iSCIB1+ significantly outperforming standard of care (SOC) double checkpoint inhibitor therapy. The combined data for the patient cohorts, significantly exceed SOC across key primary and secondary endpoints (overall response, disease control, and progression free survival (PFS)). Following these data, Scancell has chosen iSCIB1+ for further development, with plans to accelerate the pivotal registration study, and engage with the FDA before year-end. This is a significant milestone, that significantly de-risks the longer-term investment case and we expect this data to generate significant partnering interest. We reiterate our BUY, TP 25p.
